Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven

Attard, Gerhardt, Reid, Alison H M, Yap, Timothy A, Raynaud, Florence, Dowsett, Mitch, Settatree, Sarah, Barrett, Mary, Parker, Christopher, Martins, Vanessa, Folkerd, Elizabeth, Clark, Jeremy, Cooper, Colin S ORCID: https://orcid.org/0000-0003-2013-8042, Kaye, Stan B, Dearnaley, David, Lee, Gloria and de Bono, Johann S (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology, 26 (28). pp. 4563-71. ISSN 1527-7755

Full text not available from this repository. (Request a copy)

Abstract

Studies indicate that castration-resistant prostate cancer (CRPC) remains driven by ligand-dependent androgen receptor (AR) signaling. To evaluate this, a trial of abiraterone acetate-a potent, selective, small-molecule inhibitor of cytochrome P (CYP) 17, a key enzyme in androgen synthesis-was pursued.

Item Type:	Article
Uncontrolled Keywords:	adenocarcinoma,administration, oral,aged,aged, 80 and over,androstenols,castration,disease progression,humans,male,middle aged,neoplasms, hormone-dependent,prospective studies,prostatic neoplasms,treatment outcome,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Science > School of Biological Sciences Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Cancer Studies Faculty of Medicine and Health Sciences > Research Centres > Metabolic Health
Depositing User:	Pure Connector
Date Deposited:	06 Jan 2014 14:16
Last Modified:	06 Jun 2024 14:43
URI:	https://ueaeprints.uea.ac.uk/id/eprint/46147
DOI:	10.1200/JCO.2007.15.9749

Actions (login required)

View Item